ENGENEIC
EnGeneIC is a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company’s drug/siRNA delivery vehicles offer a range of choices for optimizing the delivery of clinically meaningful drug and siRNA doses to target cancer cells in-vivo. It serves customers in Australia, Singapore, Japan, and India. The company was incorporated in 2000 and is based in Lane Cove West, Australia.
ENGENEIC
Industry:
Biotechnology Life Science Therapeutics
Founded:
2000-01-01
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.engeneic.com
Total Employee:
11+
Status:
Active
Contact:
+61294205844
Email Addresses:
[email protected]
Total Funding:
16.98 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Domain Not Resolving
Current Employees Featured
Founder
Investors List
Foley Ventures
Foley Ventures investment in Series B - EnGeneIC
Shepherd Kaplan Krochuk
Shepherd Kaplan Krochuk investment in Series B - EnGeneIC
Official Site Inspections
http://www.engeneic.com
- Host name: 27.234.178.68.host.secureserver.net
- IP address: 68.178.234.27
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "EnGeneIC"
EnGeneIC - Crunchbase Company Profile & Funding
EnGeneIC is a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company’s drug/siRNA delivery vehicles offer a range of choices for …See details»
About Us - EnGeneIC
Home About Us Technology Intellectual Property Pipeline Publications Contact Powered by WordPress / Academica WordPress Theme by WPZOOMSee details»
EnGeneIC - LinkedIn
EnGeneIC | 2,156 followers on LinkedIn. First-in-class cyto-immunotherapy platform targeting the tumour directly and leveraging the patient's immune system | EngeneIC is a …See details»
EnGeneIC - LinkedIn
EngeneIC is a biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The ...See details»
Management Team - EnGeneIC
Dr. Jennifer MacDiarmid, Ph.D Dr. Himanshu Brahmbhatt, Ph.D Co-Founders, Joint-CEOs & DirectorsSee details»
EnGeneIC Company Profile - Office Locations, Competitors, …
EnGeneIC has 5 employees across 2 locations and $21.1 m in total funding,. See insights on EnGeneIC including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
EnGeneIC Pty Ltd.: Drug pipelines, Patents, Clinical trials - Synapse
EnGeneIC founders and joint CEOs, Dr Himanshu Brahmbhatt and Dr Jennifer MacDiarmid, said they were seeing high levels of neutralising antibodies against all variants, including the now …See details»
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground …
Sep 24, 2024 EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV™ (EnGeneIC Dream Vector) nanocell technology for oncology and …See details»
EnGeneIC - Contacts, Employees, Board Members, Advisors
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.See details»
Co-Founders and Joint-CEOs - EnGeneIC
Dr Himanshu Brahmbhatt Dr Jennifer MacDiarmid Co-Founders, Joint-CEOs & Directors They (popularly known as H & J) Co-founded EnGeneIC Pty Ltd in 2001 and built it from the concept stage to a company based in Australia and USA, …See details»
EnGeneIC - Funding, Financials, Valuation & Investors
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.See details»
EnGeneIC and Singapore Institute of Advanced Medicine Holdings …
Jun 7, 2024 The commercial deal will provide exclusive rights to SAM for sales of EDV therapeutics in Asia and net profits will be shared between the two companies with EnGeneIC …See details»
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground …
Sep 24, 2024 Adelaide, South Australia, September 25, 2024/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced …See details»
Foundation - EnGeneIC
The ECRF was established following public interest in an Australian Story episode, aired in 2007 and again in 2011, that documented the founding of EnGeneIC by joint CEOs Dr. Jennifer …See details»
EnGeneIC Selects Global CDMO BioCina to Advance Their
Sep 24, 2024 EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV™ (EnGeneIC Dream Vector) nanocell technology for oncology and …See details»
Tech start-ups: cancer biotech EnGeneIC raising $20 million after ...
Nov 13, 2022 Sydney-based biotech EnGeneIC is tapping investors to raise $20 million in bridging funding to buy time until the IPO market reopens and the company can undertake a …See details»
Our People - EnGeneIC
Home About Us Technology Intellectual Property Pipeline Publications Contact Powered by WordPress / Academica WordPress Theme by WPZOOMSee details»
Team Engene – EnGeneIC
Home About Us Technology Intellectual Property Pipeline Publications Contact Powered by WordPress / Academica WordPress Theme by WPZOOMSee details»